Oxidative Stress in Amyotrophic Lateral Sclerosis: Pathophysiology and Opportunities for Pharmacological Intervention
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease or Charcot disease, is a fatal neurodegenerative disease that affects motor neurons (MNs) and leads to death within 2–5 years of diagnosis, without any effective therapy available. Although the pathological mechanisms leading to ALS are still unknown, a wealth of evidence indicates that an excessive reactive oxygen species (ROS) production associated with an inefficient antioxidant defense represents an important pathological feature in ALS. Substantial evidence indicates that oxidative stress (OS) is implicated in the loss of MNs and in mitochondrial dysfunction, contributing decisively to neurodegeneration in ALS. Although the modulation of OS represents a promising approach to protect MNs from degeneration, the fact that several antioxidants with beneficial effects in animal models failed to show any therapeutic benefit in patients raises several questions that should be analyzed. Using specific queries for literature search on PubMed, we review here the role of OS-related mechanisms in ALS, including the involvement of altered mitochondrial function with repercussions in neurodegeneration. We also describe antioxidant compounds that have been mostly tested in preclinical and clinical trials of ALS, also describing their respective mechanisms of action. While the description of OS mechanism in the different mutations identified in ALS has as principal objective to clarify the contribution of OS in ALS, the description of positive and negative outcomes for each antioxidant is aimed at paving the way for novel opportunities for intervention. In conclusion, although antioxidant strategies represent a very promising approach to slow the progression of the disease, it is of utmost need to invest on the characterization of OS profiles representative of each subtype of patient, in order to develop personalized therapies, allowing to understand the characteristics of antioxidants that have beneficial effects on different subtypes of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McCord, J. M., & Fridovich, I. (1969) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)63504-5 · Cited by 12,952 · cited 1×
“This enzyme plays a key role in the antioxidant defense of the cell [75], also regulating cellular respiration and energy metabolism [76].”
BackgroundHow mitochondria produce reactive oxygen species
Murphy, M. P. (2009) · Biochemical Journal · doi:10.1042/bj20081386 · Cited by 8,207
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576 · cited 1×
“While a correlation was found between the accumulation of SOD1 aggregates and the disease progression in cervical, thoracic, and lumbar spinal cord tissues of B6-SJL-Tg (SOD1) mice, it was also suggested that an enhanced capacity of drawing the misfolded SOD1 into aggregates may confer resistance against its own toxic…”
BackgroundDeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., Nicholson, A. M., Finch, N. A., Flynn, H., Adamson, J., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.011 · Cited by 4,936 · cited 1×
“Over 50 disease-modifying genes have been described in ALS [12]; mutations in chromosome 9 open reading frame 72 (C9orf72) [13, 14], Cu/Zn superoxide dismutase type-1 (SOD1) [15–18], TAR DNABinding (TARDBP) [19], and fused in sarcoma (FUS) [20, 21] are among the most prevalent ones.”
BackgroundA Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD
Renton, A. E., Majounie, E., Waite, A., Simón-Sánchez, J., Rollinson, S., Gibbs, J. R., Schymick, J. C., Laaksovirta, H., van Swieten, J. C., Myllykangas, L., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.010 · Cited by 4,409
Free Radicals: Properties, Sources, Targets, and Their Implication in Various Diseases
Phaniendra, A., Jestadi, D. B., & Periyasamy, L. (2015) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-014-0446-0 · Cited by 2,886
TDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis
Sreedharan, J., Blair, I. P., Tripathi, V. B., Hu, X., Vance, C., Rogelj, B., Ackerley, S., Durnall, J. C., Williams, K. L., Buratti, E., et al. (2008) · Science · doi:10.1126/science.1154584 · Cited by 2,630
Zielonka, J., Joseph, J., Sikora, A., Hardy, M., Ouari, O., Vasquez-Vivar, J., Cheng, G., Lopez, M., & Kalyanaraman, B. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00042 · Cited by 1,683
Regulation of pgc-1α, a nodal regulator of mitochondrial biogenesis
Fernandez-Marcos, P. J., & Auwerx, J. (2011) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.001917 · Cited by 1,237
The sites and topology of mitochondrial superoxide production
Brand, M. D. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2010.01.003 · Cited by 1,217 · cited 4×
“AEOL 10150: Manganese [III] tetrakis[N-N′-diethylimidazolium-2-yl]porphyrin ALS: Amyotrophic lateral sclerosis ALSFRS-R: Revised amyotrophic lateral sclerosis functional rating scale ANG: Angiogenin ARE: Antioxidant response element BBB: Blood-brain barrier C9orf72: Chromosome 9 open reading frame 72 CAT: Catalase CD3…”
BackgroundInfluentialTargeting Antioxidants to Mitochondria by Conjugation to Lipophilic Cations
Murphy, M. P., & Smith, R. A. J. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105110 · Cited by 1,173 · cited 2×
“MitoQ crosses biological membranes, accumulates inside mitochondria driven by the transmembrane electric potential [255], and effectively prevents mitochondrial oxidative damage [254, 256] (Figure 3).”
BackgroundSelective Targeting of a Redox-active Ubiquinone to Mitochondria within Cells
Kelso, G. F., Porteous, C. M., Coulter, C. V., Hughes, G., Porteous, W. K., Ledgerwood, E. C., Smith, R. A. J., & Murphy, M. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009093200 · Cited by 1,091
Complex iii releases superoxide to both sides of the inner mitochondrial membrane
Muller, F. L., Liu, Y., & Van Remmen, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407715200 · Cited by 1,036
Oxidative Stress in Neurodegenerative Diseases
Niedzielska, E., Smaga, I., Gawlik, M., Moniczewski, A., Stankowicz, P., Pera, J., & Filip, M. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9337-5 · Cited by 800
Cross talk between mitochondria and NADPH oxidases
Dikalov, S. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.06.033 · Cited by 783
Zhao, K., Zhao, G.-M., Wu, D., Soong, Y., Birk, A. V., Schiller, P. W., & Szeto, H. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402999200 · Cited by 782 · cited 1×
“The capacity of SS-31 to inhibit the mPTP and cytochrome c release induced by the addition of calcium in isolated liver mitochondria [270], and its ability to protect against the loss of mitochondrial potential, and apoptosis induced by tert-butyl hydroperoxide in N2A and SH-SY5Y cells [271], suggests that this antiox…”
BackgroundQuinlan, C. L., Orr, A. L., Perevoshchikova, I. V., Treberg, J. R., Ackrell, B. A., & Brand, M. D. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.374629 · Cited by 670 · cited 1×
“Other proteins involved in mitochondrial ROS generation include cytochrome P450 (CYP) enzymes [35], dihydroorotate dehydrogenase [36, 37], complex II [38], and monoamine oxidases [39] which can also contribute to mitochondrial ROS production.”
BackgroundSnow, B. J., Rolfe, F. L., Lockhart, M. M., Frampton, C. M., O'Sullivan, J. D., Fung, V., Smith, R. A. J., Murphy, M. P., Taylor, K. M., & On behalf of the Protect Study Group (2010) · Movement Disorders · doi:10.1002/mds.23148 · Cited by 606
Estévez, A. G., Crow, J. P., Sampson, J. B., Reiter, C., Zhuang, Y., Richardson, G. J., Tarpey, M. M., Barbeito, L., & Beckman, J. S. (1999) · Science · doi:10.1126/science.286.5449.2498 · Cited by 596
Matthews, R. T., Yang, L., Browne, S., Baik, M., & Beal, M. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8892 · Cited by 557
Design, power, and interpretation of studies in the standard murine model of ALS
Scott, S., Kranz, J. E., Cole, J., Lincecum, J. M., Thompson, K., Kelly, N., Bostrom, A., Theodoss, J., Al‐Nakhala, B. M., Vieira, F. G., et al. (2008) · Amyotrophic Lateral Sclerosis · doi:10.1080/17482960701856300 · Cited by 504 · cited 1×
“Some reasons evidenced are the lack of proper blinding measurements, uniform exclusion criteria, or statistical power associated with the use of a small number of samples per group in animal assays that can lead to false-positive results and confounding biological results [272].”
BackgroundVargas, M. R., Johnson, D. A., Sirkis, D. W., Messing, A., & Johnson, J. A. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4099-08.2008 · Cited by 479
Marchetto, M. C. N., Muotri, A. R., Mu, Y., Smith, A. M., Cezar, G. G., & Gage, F. H. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.10.001 · Cited by 475
Mitochondria-targeted antioxidants protect against amyloid-β toxicity in Alzheimer's disease neurons
Manczak, M., Mao, P., Calkins, M. J., Cornea, A., Reddy, A. P., Murphy, M. P., Szeto, H. H., Park, B., & Reddy, P. H. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100564 · Cited by 469
McManus, M. J., Murphy, M. P., & Franklin, J. L. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0552-11.2011 · Cited by 432 · cited 6×
“A protective effect of MitoQ was described in chronic hepatitis C patients, by decreasing liver damage [258], as well as in some neurodegenerative diseases, including Parkinson’s [259, 260] and Alzheimer’s [261, 262] diseases, by decreasing the oxidative damage.”
BackgroundResultInfluentialGane, E. J., Weilert, F., Orr, D. W., Keogh, G. F., Gibson, M., Lockhart, M. M., Frampton, C. M., Taylor, K. M., Smith, R. A. J., & Murphy, M. P. (2010) · Liver International · doi:10.1111/j.1478-3231.2010.02250.x · Cited by 379
Effects of gender in amyotrophic lateral sclerosis
McCombe, P. A., & Henderson, R. D. (2010) · Gender Medicine · doi:10.1016/j.genm.2010.11.010 · Cited by 379 · cited 1×
“Generally, men present with an earlier age of onset compared to women, and they are more prone to spinal-onset, whereas bulbar-onset is more frequent in women [6].”
BackgroundTam, O. H., Rozhkov, N. V., Shaw, R., Kim, D., Hubbard, I., Fennessey, S., Propp, N., Phatnani, H., Kwan, J., Sareen, D., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.066 · Cited by 327 · cited 1×
“An excessive ROS production associated with an inefficient antioxidant defense represents an important pathological feature in ALS [46].”
BackgroundNAD metabolism: Implications in aging and longevity
Yaku, K., Okabe, K., & Nakagawa, T. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.05.006 · Cited by 269
Zhao, K., Luo, G., Giannelli, S., & Szeto, H. H. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.08.022 · Cited by 251 · cited 1×
“The capacity of SS-31 to inhibit the mPTP and cytochrome c release induced by the addition of calcium in isolated liver mitochondria [270], and its ability to protect against the loss of mitochondrial potential, and apoptosis induced by tert-butyl hydroperoxide in N2A and SH-SY5Y cells [271], suggests that this antiox…”
BackgroundCarrı̀, M. T., Ferri, A., Cozzolino, M., Calabrese, L., & Rotilio, G. (2003) · Brain Research Bulletin · doi:10.1016/s0361-9230(03)00179-5 · Cited by 209
Wang, H., Guo, W., Mitra, J., Hegde, P. M., Vandoorne, T., Eckelmann, B. J., Mitra, S., Tomkinson, A. E., Van Den Bosch, L., & Hegde, M. L. (2018) · Nature Communications · doi:10.1038/s41467-018-06111-6 · Cited by 205 · cited 3×
“[124] showed that the loss of nuclear FUS in fibroblasts obtained from fALS patients with the R521H and P525L FUS mutations, and in Table 1: Continued.”
BackgroundPetri, S., Kiaei, M., Damiano, M., Hiller, A., Wille, E., Manfredi, G., Calingasan, N. Y., Szeto, H. H., & Beal, M. F. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04018.x · Cited by 166 · cited 2×
“[269] in in vitro and in vivo models of ALS associated with SOD1 mutations.”
BackgroundRedox modifier genes in amyotrophic lateral sclerosis in mice
Marden, J. J., Harraz, M. M., Williams, A. J., Nelson, K., Luo, M., Paulson, H., & Engelhardt, J. F. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31265 · Cited by 145
Pervin, M., Unno, K., Nakagawa, A., Takahashi, Y., Iguchi, K., Yamamoto, H., Hoshino, M., Hara, A., Takagaki, A., Nanjo, F., et al. (2017) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2016.12.012 · Cited by 137
Inactivation of the 2‐oxo acid dehydrogenase complexes upon generation of intrinsic radical species
Bunik, V. I., & Sievers, C. (2002) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2002.03204.x · Cited by 134 · cited 1×
“The O2 •- is produced at a number of sites in mitochondria, including complexes I and III of the electron transport chain [27, 29], pyruvate dehydrogenase [30], and 2-oxoglutarate dehydrogenase [31, 32], all directing ROS towards the mitochondrial matrix (MM), glycerol 3phosphate dehydrogenase [33] that produces ROS t…”
BackgroundOmura, T. (2006) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.06.008 · Cited by 117
Chico, L., Ienco, E. C., Bisordi, C., Lo Gerfo, A., Petrozzi, L., Petrucci, A., Mancuso, M., & Siciliano, G. (2018) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527317666180720162029 · Cited by 95 · cited 1×
“Moreover, in a double-blind clinical trial, curcumin oral supplementation (600mg/day, Brainoil) in 42 ALS patients during 6 months resulted in a decrease in ALS progression, improvement of aerobic metabolism, and a reduction of oxidative damage [175] (Table 2).”
BackgroundHarlan, B. A., Pehar, M., Sharma, D. R., Beeson, G., Beeson, C. C., & Vargas, M. R. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.698779 · Cited by 94
de la Rubia, J. E., Drehmer, E., Platero, J. L., Benlloch, M., Caplliure-Llopis, J., Villaron-Casales, C., de Bernardo, N., AlarcÓn, J., Fuente, C., Carrera, S., et al. (2019) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2018.1536152 · Cited by 92 · cited 5×
“The results of this trial showed that EH301 significantly slowed the progression of ALS compared to placebo, also showing improvements in several key outcome measures compared with baseline [253] (Table 2).”
BackgroundMethodResultInfluentialAn increase of oxidized coenzyme Q-10 occurs in the plasma of sporadic ALS patients
Sohmiya, M., Tanaka, M., Suzuki, Y., Tanino, Y., Okamoto, K., & Yamamoto, Y. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.09.030 · Cited by 69
Körner, S., Böselt, S., Thau, N., Rath, K. J., Dengler, R., & Petri, S. (2013) · Neurodegenerative Diseases · doi:10.1159/000338048 · Cited by 64 · cited 1×
“Decreased SIRT1 levels have been found in postmortem tissues from ALS patients [244] and intraperitoneal injection of the SIRT1 activator resveratrol resulted in a significant improvement in both symptoms and survival of SOD1 mice [245].”
BackgroundHarlan, B. A., Pehar, M., Killoy, K. M., & Vargas, M. R. (2019) · The FASEB Journal · doi:10.1096/fj.201802752r · Cited by 50 · cited 3×
“Increasing total NAD+ content in astrocytes using NMN (5mM and 24h) was reported to induce the activation of Nrf2 and upregulation of the antioxidant proteins HO-1 and sulfiredoxin 1 (SRXN1), mediated by SIRT6 [252].”
BackgroundInfluential
Cited by
Dash, U. C., Bhol, N. K., Swain, S. K., Samal, R. R., Nayak, P. K., Raina, V., Panda, S. K., Kerry, R. G., Duttaroy, A. K., & Jena, A. B. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.10.004 · Cited by 700
Free radicals and their impact on health and antioxidant defenses: a review
Chandimali, N., Bak, S. G., Park, E. H., Lim, H.-J., Won, Y.-S., Kim, E.-K., Park, S.-I., & Lee, S. J. (2025) · Cell Death Discovery · doi:10.1038/s41420-024-02278-8 · Cited by 669
Deubiquitinating enzymes (DUBs): Regulation, homeostasis, and oxidative stress response
Snyder, N. A., & Silva, G. M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101077 · Cited by 347
Janse van Mantgem, M. R., van Rheenen, W., Hackeng, A. V., van Es, M. A., Veldink, J. H., van den Berg, L. H., & van Eijk, R. P. A. (2023) · Neurology · doi:10.1212/wnl.0000000000201657 · Cited by 28
“The variation may be explained by (1) differences in the disease stage and the phenotype of the population enrolled, and (2) differences in study methodology (e.”
BackgroundMethodInfluential
Metadata
- Authors
- Cunha-Oliveira, T., Montezinho, L., Mendes, C., Firuzi, O., Saso, L., Oliveira, P. J., & Silva, F. S. G.
- Venue
- Oxidative Medicine and Cellular Longevity
- Publisher
- Wiley
- Published
- 2020-11-15
- Volume
- 2020
- Pages
- 1-29
- ISSN
- 1942-0994 (ISSN-L)
- 1942-0900
- OpenAlex
- W3098705707
- Cited by
- 206
- References
- 44
- FWCI
- 7.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.